Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.39 |
| ▸ | PREP | P48147 | 4/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954502 | 1.00 | CA1 (0.52) | CA1CA12CA9CA2ENPP2 | |
| SCHEMBL282583 | 0.84 | CA1 (0.50) | CA1CA12CA9CA2ENPP2 | |
| SCHEMBL1881020 | 0.82 | ENPP2 (0.56) | CA1CA12CA9CA2ENPP2 | |
| SCHEMBL7127684 | 0.82 | CA12 (0.57) | CA1CA12CA9PREPHSP90AA1 | |
| SCHEMBL13196942 | 0.80 | CA1 (0.39) | CA1CA12CA9CA2ENPP2 | |
| SCHEMBL2523819 | 0.78 | CA12 (0.56) | CA1CA12CA9PREPHIF1A | |
| SCHEMBL12017833 | 0.78 | CA1 (0.59) | CA1CA12CA9CA2PREP | |
| SCHEMBL9988018 | 0.78 | CA1 (0.38) | CA1CA12CA9CA2ENPP2 | |
| SCHEMBL1680165 | 0.77 | CA12 (0.55) | CA1CA12CA9PREPHSP90AA1 | |
| SCHEMBL30186537 | 0.76 | CA12 (0.58) | CA1CA12CA9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980668-B2 | Photoluminescent nanostructure-based sensors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-29 | — | — | US | claimed |
| EP-2739977-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | Massachusetts Institute of Technology (US) | 2014-06-11 | — | — | EP | claimed |
| US-20130035567-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | NATIONAL SCIENCE FOUNDATION | 2013-02-07 | — | — | US | claimed |
| WO-2013019722-A1 | PHOTOLUMINESCENT NANOSTRUCTURE-BASED SENSORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-02-07 | — | — | WO | claimed |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2020-04-28 | — | — | US | disclosed |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2020-04-28 | — | — | US | disclosed |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | disclosed |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-20100215579-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (PA) | 2010-08-26 | — | — | US | disclosed |
| US-20100215579-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (PA) | 2010-08-26 | — | — | US | disclosed |
| EP-2144916-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | The Trustees of the University of Pennsylvania (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7589239-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2009-09-15 | — | — | US | disclosed |
| US-7468462-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008124812-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080221069-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | PNCK, TXK, CAMKK1 | CA1 897/4885CA12 3263/4885CA9 3281/4885 |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, TXK, CAMKK1 | CA1 897/4885CA12 3263/4885CA9 3281/4885 |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | CHEK2, CHEK1, DCK | CA1 3797/4885CA12 3778/4885CA9 1199/4885 |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | CHEK2, CHEK1, DCK | CA1 3797/4885CA12 3778/4885CA9 1199/4885 |
| US-20080221069-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | GPR119, IGF1R, GCKR | CA1 4762/4885CA12 3834/4885CA9 3533/4885 |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | GPR119, IGF1R, CCNE2 | CA1 4763/4885CA12 3832/4885CA9 3448/4885 |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, CAMKK1, CILK1 | CA1 928/4885CA12 3247/4885CA9 3391/4885 |
| US-20100215579-A1 | PHEN-NAPHTHALENE AND PHEN-QUINOLINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | APP, PSEN1, PSEN2 | CA1 2676/4885CA12 3276/4885CA9 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.